Stephens analyst Raj Kumar raised the firm’s price target on Guardian Pharmacy (GRDN) to $36 from $35 and keeps an Overweight rating on the shares after the company reaffirmed its 2025 revenue and adjusted EBITDA guidance while initiating its 2026 outlook and announced it completed its acquisition of a single LTC pharmacy location in Montana.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy Reaffirms 2025 Outlook, Issues 2026 Guidance
- Guardian Pharmacy affirms FY25 revenue view of $1.43B-$1.45B, consensus $1.44B
- Guardian Pharmacy sees FY26 revenue of $1.40B-$1.42B, consensus $1.45B
- Guardian Pharmacy down 2% at $30.65 after affirmed FY25, initial FY26 outlook
- Guardian Pharmacy price target raised to $34 from $30 at Truist